MOUNJARO is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Eli Lilly And Company. The primary component is Tirzepatide.
Product ID | 0002-1484_47ab0499-a914-4b28-8649-e7e7a6e6912b |
NDC | 0002-1484 |
Product Type | Human Prescription Drug |
Proprietary Name | MOUNJARO |
Generic Name | Tirzepatide |
Dosage Form | Injection, Solution |
Route of Administration | SUBCUTANEOUS |
Marketing Start Date | 2022-05-13 |
Marketing Category | NDA / |
Application Number | NDA215866 |
Labeler Name | Eli Lilly and Company |
Substance Name | TIRZEPATIDE |
Active Ingredient Strength | 8 mg/.5mL |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2022-05-13 |
NDC Exclude Flag | N |
Sample Package? | N |
NDC | Brand Name | Generic Name |
---|---|---|
0002-1457 | MOUNJARO | tirzepatide |
0002-1460 | MOUNJARO | tirzepatide |
0002-1471 | MOUNJARO | tirzepatide |
0002-1484 | MOUNJARO | tirzepatide |
0002-1495 | MOUNJARO | tirzepatide |
0002-1506 | MOUNJARO | tirzepatide |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
MOUNJARO 97668206 not registered Live/Pending |
Eli Lilly and Company 2022-11-08 |
MOUNJARO 97596856 not registered Live/Pending |
Eli Lilly and Company 2022-09-19 |
MOUNJARO 97468410 not registered Live/Pending |
Eli Lilly and Company 2022-06-21 |
MOUNJARO 88680946 not registered Live/Pending |
Eli Lilly and Company 2019-11-05 |